Comparative Pharmacology
Head-to-head clinical analysis: ALOGLIPTIN versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOGLIPTIN versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
ALOGLIPTIN vs SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
25 mg orally once daily
Oral, initial dose based on prior therapy and glycemic control: 50 mg sitagliptin / 500 mg metformin twice daily or 50 mg sitagliptin / 1000 mg metformin twice daily. Max sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Clinical Note
moderateAlogliptin + Gatifloxacin
"Alogliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAlogliptin + Rosoxacin
"Alogliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateAlogliptin + Levofloxacin
"Alogliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateAlogliptin + Trovafloxacin
"Alogliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Metformin: Terminal half-life ~6.2 hours (plasma), but prolonged to ~17.6 hours in renal impairment; clinical context: dosing interval adjusted for CrCl. Sitagliptin: Terminal half-life ~12.4 hours, allows once-daily dosing.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Metformin: 90% renal unchanged (active tubular secretion), 10% fecal. Sitagliptin: 87% renal (active tubular secretion), 13% fecal (biliary excretion minimal for sitagliptin, but fecal includes unabsorbed drug).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor